Core Viewpoint - Fuhong Hanlin (02696) shares increased by over 5%, currently trading at 70.15 HKD with a transaction volume of 16.35 million HKD, driven by the announcement of their participation in ESMO ASIA 2025 [1] Group 1: Upcoming Event - ESMO ASIA 2025 will be held from December 5 to December 7 in Singapore [1] - Fuhong Hanlin will present four products at the conference, including HLX43 (PD-L1 ADC), H drug Hanshu (Sru Li monoclonal antibody, European brand name: Hetronifly), HLX11 (biosimilar of Pertuzumab, US brand name: POHERDY), and HLX78 (Lasofoxifene tablets) [1] - The company will showcase 10 latest research data through oral presentations and posters, highlighting its diverse layout and cutting-edge exploration in cancer treatment [1] Group 2: Clinical Data - The Phase II clinical data for the broad-spectrum anti-tumor ADC HLX43 in the cervical cancer field will be released for the first time at the conference [1]

Core Viewpoint - Fuhong Hanlin (02696) shares increased by over 5%, currently trading at 70.15 HKD with a transaction volume of 16.35 million HKD, following the announcement of their participation in ESMO ASIA 2025 in Singapore from December 5 to December 7 [1] Group 1: Company Developments - Fuhong Hanlin will present four products at the ESMO ASIA 2025 conference, including HLX43 (PD-L1 ADC), H drug Hansu (Sruvelizumab, European brand name: Hetronifly), HLX11 (biosimilar of Pertuzumab, US brand name: POHERDY), and HLX78 (Lasofoxifene tablets) [1] - The company will showcase ten latest research data, highlighting its diversified layout and cutting-edge exploration in the field of cancer treatment [1] - Notably, the Phase II clinical data for the broad-spectrum anti-tumor ADC HLX43 in cervical cancer will be presented for the first time at the conference [1]